Nanjing Vazyme Biotech Co., Ltd. Class ASSE: 688105

"NANJING VAZYME BIOTECH CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Biological Products and CXO Industry

Aug 28, 2026 · Issued by Nanjing Vazyme Biotech Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Biological Products and CXO Industry

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Nanjing Vazyme Biotech Co., Ltd. Class A

Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue GrowthAug 26
"NANJING VAZYME BIOTECH CO., LTD."Indicative Announcement on Change in Equity Interests of a Shareholder Holding More Than 5% of Shares Reaching the 1% and 5% Thresholds and Disclosure of Simplified Report on Changes in Equity InterestsJul 29
"NANJING VAZYME BIOTECH CO., LTD."Indicative Announcement on Progress of Shareholding Increase by the Controlling Shareholder and Equity Change Reaching the 1% ThresholdJul 25
Announcement on the 1st Share Increase by Controlling Shareholder and Implementation Progress of the Share Increase PlanJun 23

All Nanjing Vazyme Biotech Co., Ltd. Class A news releases